Economic analysis of palivizumab in infants with congenital heart disease.
about
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenMonoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenA decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.Respiratory syncytial virus bronchiolitis.Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy.Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom.Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases.Cost-effectiveness of prenatal screening strategies for congenital heart disease.A review of cost-effectiveness of palivizumab for respiratory syncytial virus.New perspectives in Respiratory Syncitial Virus infection.Respiratory syncytial virus hospitalisation trends in children with haemodynamically significant heart disease, 1997-2012.Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.Direct non-medical and indirect costs for families with children with congenital cardiac defects in Germany: a survey from a university centre.Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in childrenCongenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model
P2860
Q24197915-D9BB0166-11EE-45AE-B695-7DA99B014ED9Q24234622-62EA0DE5-97DD-4047-B403-C6CE858CEC85Q34884984-E1866849-77A0-4146-B7F3-D6865CA6E34FQ36361899-E8BE1BE2-0DF3-4962-9DDC-BD1987C7D6FEQ36731851-EEE74B99-02BC-4B1F-BADA-4058BDCB4547Q36814797-A6FD43E4-4149-4F48-8DCA-ECCC60D99A47Q36869107-D478A284-5B3B-449B-937E-162295207445Q36922280-8CC5181C-EED8-426B-944D-9A7529E964F6Q37075484-717C325F-75CF-497E-B1E0-70380A9D7588Q37290618-0083A8DF-B00B-430A-BCBC-3F855CF8BF12Q37318542-151F8403-A826-43B3-9C42-E4E92ADCE740Q37613083-BACC459E-C216-4C2B-8F77-B05D75516E3EQ38058838-23CCDFDD-0158-464A-8BE1-848616239143Q38141087-AD0E8205-3698-4DAA-A7B2-DB84A4C07F82Q39781387-26CBB452-688A-4E1E-BEDE-98758C3370A0Q41778509-5735D271-E7F4-4351-8BF3-9C1AA6A1D9C5Q44556859-C139FA43-80A2-45F0-8D94-4455B64E5721Q45375474-7A4D8C73-5AD1-4DAC-93B9-00130E031424Q47112273-8DF1CC89-95A2-4AC2-8AAA-E03A405BA340Q49720574-F4166BD2-C584-4A80-B06E-2933B02D72C9Q51411926-1F5BA374-F7A0-49DC-84DF-45D04AA699C0Q51779758-B2478762-D1E9-4244-AB54-3D5E1161DB65Q57570436-1EA3EA77-4179-4730-8288-121904194C54Q58691537-B759D27A-DA36-405C-87CA-8E33C6B4F212
P2860
Economic analysis of palivizumab in infants with congenital heart disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Economic analysis of palivizumab in infants with congenital heart disease.
@en
Economic analysis of palivizumab in infants with congenital heart disease.
@nl
type
label
Economic analysis of palivizumab in infants with congenital heart disease.
@en
Economic analysis of palivizumab in infants with congenital heart disease.
@nl
prefLabel
Economic analysis of palivizumab in infants with congenital heart disease.
@en
Economic analysis of palivizumab in infants with congenital heart disease.
@nl
P356
P1433
P1476
Economic analysis of palivizumab in infants with congenital heart disease.
@en
P2093
Laura E Yount
William T Mahle
P304
P356
10.1542/PEDS.2004-0224
P407
P577
2004-12-01T00:00:00Z